Apixaban Market - Size, Share, Outlook, and Forecast till 2026

Worldwide Market Reports added Latest Research Report titled “Apixaban Market - Size, Share, Outlook, and Forecast till 2026" to its Large Report database.

Apixaban is an anticoagulant used to reduce blood clotting and risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is an oral factor Xa inhibitor and is sold under the trade name Eliquis. It was approved in Europe in 2012 and in the U.S. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban was developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Get Sample copy of research report:https://www.worldwidemarketreports.com/sample/196789

Increasing geriatric population and prevalence of atrial fibrillation in people over 80 years old are major factors that are expected to drive growth of apixaban market over the forecast period. Moreover, increasing incidences of deep vein thrombosis and pulmonary embolism is another factor boosting growth of apixaban market. Also, increasing investment in research and development activities in the pharmaceutical sector and launch of innovative oral anticoagulant drugs are fueling the market growth.

However, stringent regulations by governments and risk of side-effects and complications associated with the usage of oral anticoagulants is expected to hinder growth of the global apixaban market.

Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/196789

Key Developments in Apixaban Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the apixaban market. On March 6, 2017, Bristol-Myers Squibb and Pfizer announced that they will present new analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session.

Bristol-Myers Squibb Company and Pfizer reported that they have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with Acute Coronary Syndrome (ACS) who were treated with apixaban or placebo in addition to mono or dual antiplatelet therapy. The study was stopped at an early stage based on the recommendation of an independent Data Monitoring Committee (DMC).

On December 5, 2017, Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the around seven million people in the U.S. in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.

Some of the major players in the global apixaban market include Pfizer, Medichem, Polpharma, Beijing Cooperate Pharmaceutical, Centaur Pharmaceutical, DEAFARMA, and Dipharma Francis among others.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

#3200

Seattle, WA 98154,

U.S

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

WEBSITE : https://www.worldwidemarketreports.com/

Visit Our News Website: https://www.industrychronicle.com/

This release was published on openPR.